Sermorelin: The GHRH Analog With the Longest Clinical Track Record

What it is

GHRH, the hormone your brain uses to tell the pituitary to release growth hormone, is 44 amino acids long. Only the first 29 do the work. Sermorelin is those 29, made in a lab. It binds the same receptor as the full hormone, lasts about 10 to 20 minutes, and is cleared. Every other GHRH-type peptide on this site, CJC-1295 included, is a modification of this molecule built to last longer.

Sermorelin’s distinction is its history. The FDA approved it in 1997, as Geref, for children who were short because their pituitaries did not make enough growth hormone. Doctors prescribed it for about a decade. In 2008 the manufacturer withdrew it, not for a safety problem but because recombinant growth hormone had taken the market. Since then it has lived on through compounding pharmacies, mostly in anti-aging clinics, and as a research chemical.

What it is studied for

Growth in children with growth hormone deficiency, the approved use. Growth hormone and IGF-1 levels in older adults. Deep sleep. And as a test dose to check whether a pituitary responds. The anti-aging use it is now sold for has never had a trial.

What the evidence actually shows

In humans

The pediatric data is the deepest. Trials in children with growth hormone deficiency showed sermorelin increased growth velocity, and a decade of prescribing produced the longest safety record of any peptide in this class (Walker et al., 1990). The idea behind using it in children was that stimulating the pituitary might help it develop, rather than replacing its output with injected growth hormone.

In healthy older men, a controlled study gave a single bedtime injection of GHRH 1-29 for two weeks. Nighttime growth hormone pulses got bigger and IGF-1 rose toward younger-adult levels (Vittone et al., 1997). That shows an aging pituitary still responds. It does not show that responding makes anyone stronger, leaner, or healthier; the study was too short and too small to measure that, and no one has run the longer one.

GHRH also deepens sleep. Growth hormone is released mostly during slow-wave sleep, and GHRH given at night increases slow-wave sleep time, an effect that may be separate from the hormone itself (Steiger, 2011). Better sleep is the effect users mention most.

What is missing

A trial of sermorelin in adults for body composition, strength, or any aging outcome. The clinics prescribing it for that are working from the mechanism and from the pediatric safety record, not from a trial in their patients’ age group.

From user reports

Deeper sleep within the first week, slow changes in body fat and recovery over months, and the mild water retention and tingling that come with growth hormone. Some report nothing at all, which fits a drug whose effect depends on how much pituitary reserve the user still has.

How it works

Sermorelin binds the GHRH receptor on pituitary cells and triggers a pulse of growth hormone, which raises IGF-1. Because it clears in minutes, the pulse looks like the body’s own, and the normal feedback loops stay intact: the pituitary can still say no. That is the safety argument for it over injected growth hormone and over long-acting CJC-1295 with DAC. The short life is also the limitation: it only works if the pituitary still has capacity, which declines with age, and it needs daily injection.

Somatostatin, the brake on growth hormone, still applies. That is why sermorelin works best at bedtime and fasted, and why people pair it with a ghrelin-type peptide like ipamorelin, which partly lifts the brake.

How it is used in studies

The pediatric dose was 30 micrograms per kilogram once a day at bedtime. The older-adult study used 2 mg nightly. Clinics prescribe 200 to 500 micrograms under the skin at bedtime, sometimes split morning and night, often with ipamorelin in the same syringe, in cycles of three to six months. Compounded vials are mixed with bacteriostatic water and refrigerated; see the storage guide.

Side effects and unknowns

From the approved-drug era: injection-site redness or pain in about one in six, flushing, headache, dizziness, and occasional nausea; rare allergic reactions. From the growth hormone class: water retention, joint aches, tingling in the hands. Blood sugar can drift up, and IGF-1 should be monitored to keep it in range.

The pediatric record answers the question “is a few years of sermorelin safe in a growing child?” It does not answer “is a decade of sermorelin safe in a 60-year-old?” The IGF-1 and cancer question that hangs over every growth hormone peptide applies here too. See the safety guide.

How it compares

• CJC-1295: the same molecule with swaps for stability (no DAC, ~30 minutes) or an albumin hook (DAC, about a week). Bigger pulses, no approval history, one human trial.
• Tesamorelin: the full 44-amino-acid GHRH with a protective cap, currently FDA approved, with Phase III data for belly fat. The best-evidenced of the three.
• Ipamorelin and GHRP-2: ghrelin-type; stacked with sermorelin rather than swapped for it. See the muscle growth guide.
• MK-677: oral, all-day, more human data, more hunger and blood-sugar effect.

Legal status

Formerly FDA approved as Geref; withdrawn in 2008 for commercial reasons. No approved sermorelin product exists in the United States today. It is prescribed off-label through compounding pharmacies, which the FDA has periodically restricted, and sold as a research chemical. WADA bans GHRH and its analogs.

Bottom line

Sermorelin is the GHRH peptide with the longest human safety record, earned in children, and no trial for the anti-aging use it is now prescribed for. It reliably raises growth hormone in adults who still have pituitary reserve. If you want a GHRH peptide with a track record, this or tesamorelin is the choice; if you want proof it does something for a healthy 55-year-old, nobody has that.

References

1. Walker RF, et al. (1990). Growth hormone releasing peptides: a review of clinical studies. Growth Horm IGF Res. PubMed
2. Vittone J, et al. (1997). Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. PubMed
3. Steiger A, et al. (2011). Ghrelin and sleep-wake regulation. Rev Endocr Metab Disord. PubMed

See also

• Peptide
  GHRP-2: What the Research Shows About This Second-Generation GH Secretagogue

  GHRP-2 is a six-amino-acid peptide that copies ghrelin, the hunger hormone, to make the pituitary release a pulse of growth hormone. Japan approved it as a one-dose diagnostic test; no one has trialed it as a treatment.

• Peptide
  GHRP-6: What the Research Shows About This Growth Hormone Releasing Peptide

  GHRP-6 is the six-amino-acid peptide that led to the discovery of the ghrelin receptor. It reliably releases growth hormone in people and makes them very hungry. No trial has tested it for muscle or recovery.

• Peptide
  CJC-1295: What the Evidence Says About This GHRH Analog

  CJC-1295 is a longer-lasting version of GHRH, the signal that tells the pituitary to release growth hormone. The DAC form raised GH and IGF-1 for days in one small trial; the no-DAC form (Mod GRF 1-29) has no human trial of its own.